Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the 8 Best Genomics Stocks to Buy According to Analysts. On May 28, Ionis ...

On Tuesday, Ionis Pharmaceuticals Inc (NASDAQ:IONS) and Ono Pharmaceutical Co., Ltd entered into a license agreement in which Ono obtains exclusive global rights for the development and ...

Ionis Pharmaceuticals has revenue from commercialized medicines, but those products reached the market in the hands of biopharma industry partners. The genetic medicines company does have wholly owned ...

Ionis Pharmaceuticals IONS reported first-quarter 2025 adjusted loss of 75 cents per share, narrower than the Zacks Consensus Estimate of a loss of $1.11. In the year-ago period, the company posted an ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the appointment of Ludwig Hantson, Ph.D., an accomplished global ...

This is a new position for Capricorn Fund Managers Ltd, representing 3.58% of 13F reportable AUM as of September 30, 2025. Top holdings after the filing: WAY: $19.15 million (6.4% of AUM) as of ...

Eli Lilly Earnings: Revenue Increases Reflect Global Demand for Oral Obesity Therapies ...

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

CARLSBAD, Calif. & OSAKA, Japan--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Ono Pharmaceutical Co., Ltd (Ono), today announced that the two companies have entered into a license ...

On Wednesday, Ionis Pharmaceuticals Inc (NASDAQ:IONS) reported a fourth-quarter EPS loss of $0.66, up from a loss of $0.06, beating the consensus of a $1.10 loss. The company reported an adjusted net ...

The fair value estimate for Ionis Pharmaceuticals has shifted from US$96.73 to US$100.92, a modest reset that puts fresh numbers around the stock. This move comes during an active period of Street ...